STOCK TITAN

Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.

Loading...
Loading translation...
Argus Session date unavailable
-1.34% session move Open Argus
Details

News Market Reaction – XENE

The recorded move for XENE in the trading session of this news was -1.34%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.

Fireside Chat Details:


 Date:Thursday, September 8, 2022
   
 Time:11:35 am -12:05 pm ET
   
 Presenters:
Ian Mortimer, President and CEO
Chris Von Seggern, CCO 


A webcast of the fireside chat will be available on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Xenon Pharmaceuticals participate in the Wells Fargo Securities Healthcare Conference?

Xenon Pharmaceuticals will participate in the Wells Fargo Securities Healthcare Conference from September 7-9, 2022.

What is the schedule for Xenon's fireside chat at the conference?

Xenon's fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET.

Who will present during Xenon's fireside chat?

The presenters during Xenon's fireside chat will be President and CEO Ian Mortimer and CCO Chris Von Seggern.

Where can I watch the webcast of Xenon's fireside chat?

The webcast of Xenon's fireside chat will be available in the 'Investors' section of their website.

What is the focus of Xenon Pharmaceuticals?

Xenon Pharmaceuticals focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy.

Keep reading